Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 10Active not recruiting 10Recruiting 8Not yet recruiting 6Unknown 4Terminated 4Withdrawn 1No longer available 1Enrolling by invitation 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Lymphoid 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Recurrence 1

Interventions

Carboplatin 132Cisplatin 129Pemetrexed 114Docetaxel 81Drug Therapy 62Gefitinib 57anlotinib 55Gemcitabine 55Erlotinib Hydrochloride 55Radiotherapy 48Bevacizumab 48pembrolizumab 47Paclitaxel 47Etoposide 44apatinib 42icotinib 41camrelizumab 39osimertinib 36Nivolumab 33Vinorelbine 31Radiosurgery 30sintilimab 29durvalumab 25aumolertinib 25endostar protein 24atezolizumab 22Endostatins 22toripalimab 19Blood Specimen Collection 19tislelizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × lorlatinib × Thoracic × Clear all
NCT03612154 2022-04-06

Study of Lorlatinib in ROS1 Rearranged NSCLC

National Cancer Center, Korea

Phase 2 Unknown
35 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03439215 2021-07-19

PFROST

Fondazione Ricerca Traslazionale

Phase 2 Unknown
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown
96 enrolled
Thoracic

Lung Neoplasms, Recurrence

NCT02927340 2021-03-09

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Massachusetts General Hospital

Phase 2 Unknown
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡